Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.

Gfeller D, Guillaume P, Michaux J, Pak HS, Daniel RT, Racle J, Coukos G, Bassani-Sternberg M.

J Immunol. 2018 Nov 14. pii: ji1800914. doi: 10.4049/jimmunol.1800914. [Epub ahead of print]

PMID:
30429286
2.

A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.

Ghosn J, Vicino A, Michielin O, Coukos G, Kuntzer T, Obeid M.

J Immunother Cancer. 2018 Oct 22;6(1):110. doi: 10.1186/s40425-018-0429-4.

3.

Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor.

Soler M, Li X, John-Herpin A, Schmidt J, Coukos G, Altug H.

ACS Sens. 2018 Oct 19. doi: 10.1021/acssensors.8b00523. [Epub ahead of print]

PMID:
30339020
4.

50 Gy Stereotactic Body Radiation Therapy to the Dominant Intra-Prostatic Nodule: Results from a Phase Ia/b Trial.

Herrera FG, Valerio M, Berthold D, Tawadros T, Meuwly JY, Vallet V, Baumgaertner P, Thierry AC, De Bari B, Jichlinski P, Kandalaft L, Coukos G, Harari A, Bourhis J.

Int J Radiat Oncol Biol Phys. 2018 Sep 26. pii: S0360-3016(18)33803-3. doi: 10.1016/j.ijrobp.2018.09.023. [Epub ahead of print]

5.

Correction to: CART cells are prone to Fas- and DR5-mediated cell death.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A.

J Immunother Cancer. 2018 Sep 25;6(1):92. doi: 10.1186/s40425-018-0410-2.

6.

Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches.

Digklia A, Duran R, Homicsko K, Kandalaft LE, Hocquelet A, Orcurto A, Coukos G, Denys A.

Cardiovasc Intervent Radiol. 2018 Sep 12. doi: 10.1007/s00270-018-2074-1. [Epub ahead of print]

PMID:
30209564
7.

Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome.

Mylonas R, Beer I, Iseli C, Chong C, Pak HS, Gfeller D, Coukos G, Xenarios I, Müller M, Bassani-Sternberg M.

Mol Cell Proteomics. 2018 Aug 31. pii: mcp.RA118.000877. doi: 10.1074/mcp.RA118.000877. [Epub ahead of print]

8.

Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network.

Grass F, Martin D, Montemurro M, Mathevet P, Wolfer A, Coukos G, Demartines N, Hübner M.

Chemotherapy. 2018;63(3):143-147. doi: 10.1159/000488774. Epub 2018 Jun 13.

PMID:
29898438
9.

Label-Free Optofluidic Nanobiosensor Enables Real-Time Analysis of Single-Cell Cytokine Secretion.

Li X, Soler M, Szydzik C, Khoshmanesh K, Schmidt J, Coukos G, Mitchell A, Altug H.

Small. 2018 Jun;14(26):e1800698. doi: 10.1002/smll.201800698. Epub 2018 May 28.

PMID:
29806234
10.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 May 15. doi: 10.1007/s10456-018-9613-x. [Epub ahead of print] Review.

11.

The C-terminal extension landscape of naturally presented HLA-I ligands.

Guillaume P, Picaud S, Baumgaertner P, Montandon N, Schmidt J, Speiser DE, Coukos G, Bassani-Sternberg M, Filippakopoulos P, Gfeller D.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):5083-5088. doi: 10.1073/pnas.1717277115. Epub 2018 Apr 30.

12.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
13.

T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan3311. doi: 10.1126/scitranslmed.aan3311.

PMID:
29643229
14.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.

Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.

15.

Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.

Yuan X, Yang M, Chen X, Zhang X, Sukhadia S, Musolino N, Bao H, Chen T, Xu C, Wang Q, Santoro S, Ricklin D, Hu J, Lin R, Yang W, Li Z, Qin W, Zhao A, Scholler N, Coukos G.

Cancer Immunol Immunother. 2018 Feb;67(2):329-339. doi: 10.1007/s00262-017-2101-0.

PMID:
29313073
16.

Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.

Guo Y, Hu J, Wang Y, Peng X, Min J, Wang J, Matthaiou E, Cheng Y, Sun K, Tong X, Fan Y, Zhang PJ, Kandalaft LE, Irving M, Coukos G, Li C.

Eur J Cancer. 2018 Feb;90:111-121. doi: 10.1016/j.ejca.2017.10.035. Epub 2018 Jan 4.

PMID:
29304474
17.

Immune-related adverse events of immune checkpoint inhibitors and the impact of sex-what we know and what we need to learn.

Özdemir BC, Coukos G, Wagner AD.

Ann Oncol. 2018 Apr 1;29(4):1067. doi: 10.1093/annonc/mdx818. No abstract available.

PMID:
29300807
18.

Cancer immunotherapy full speed ahead.

Melero I, Navarro B, Teijeira A, Coukos G.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii1-xii2. doi: 10.1093/annonc/mdx739. No abstract available.

PMID:
29253117
19.

High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.

Chong C, Marino F, Pak H, Racle J, Daniel RT, Müller M, Gfeller D, Coukos G, Bassani-Sternberg M.

Mol Cell Proteomics. 2018 Mar;17(3):533-548. doi: 10.1074/mcp.TIR117.000383. Epub 2017 Dec 14.

20.

'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.

Müller M, Gfeller D, Coukos G, Bassani-Sternberg M.

Front Immunol. 2017 Oct 20;8:1367. doi: 10.3389/fimmu.2017.01367. eCollection 2017.

21.

Mechanisms regulating T-cell infiltration and activity in solid tumors.

Lanitis E, Dangaj D, Irving M, Coukos G.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii18-xii32. doi: 10.1093/annonc/mdx238.

PMID:
29045511
22.

Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.

Facciabene A, De Sanctis F, Pierini S, Reis ES, Balint K, Facciponte J, Rueter J, Kagabu M, Magotti P, Lanitis E, DeAngelis RA, Buckanovich RJ, Song WC, Lambris JD, Coukos G.

Oncoimmunology. 2017 Jun 8;6(9):e1326442. doi: 10.1080/2162402X.2017.1326442. eCollection 2017.

23.

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.

Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclément C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derré L, Jandus C.

Nat Commun. 2017 Sep 19;8(1):593. doi: 10.1038/s41467-017-00678-2.

24.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
25.

Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.

Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon PO, Kandalaft LE, Coukos G, Gfeller D.

PLoS Comput Biol. 2017 Aug 23;13(8):e1005725. doi: 10.1371/journal.pcbi.1005725. eCollection 2017 Aug.

26.

Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven iterative survival analysis.

Crespo I, Götz L, Liechti R, Coukos G, Doucey MA, Xenarios I.

NPJ Syst Biol Appl. 2016 Dec 22;2:16037. doi: 10.1038/npjsba.2016.37. eCollection 2016.

27.

The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β2-Microglobulin through Distinct Binding Sites.

Merkle PS, Irving M, Hongjian S, Ferber M, Jørgensen TJD, Scholten K, Luescher I, Coukos G, Zoete V, Cuendet MA, Michielin O, Rand KD.

Biochemistry. 2017 Aug 1;56(30):3945-3961. doi: 10.1021/acs.biochem.7b00385. Epub 2017 Jul 19.

PMID:
28671821
28.

In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.

Schmidt J, Guillaume P, Dojcinovic D, Karbach J, Coukos G, Luescher I.

J Biol Chem. 2017 Jul 14;292(28):11840-11849. doi: 10.1074/jbc.M117.789511. Epub 2017 May 23.

29.

TIE-2 expressing monocytes in human cancers.

Turrini R, Pabois A, Xenarios I, Coukos G, Delaloye JF, Doucey MA.

Oncoimmunology. 2017 Mar 16;6(4):e1303585. doi: 10.1080/2162402X.2017.1303585. eCollection 2017.

30.

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.

Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.

Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.

31.

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.

Irving M, Vuillefroy de Silly R, Scholten K, Dilek N, Coukos G.

Front Immunol. 2017 Apr 3;8:267. doi: 10.3389/fimmu.2017.00267. eCollection 2017. Review.

32.

The ovarian cancer oncobiome.

Banerjee S, Tian T, Wei Z, Shih N, Feldman MD, Alwine JC, Coukos G, Robertson ES.

Oncotarget. 2017 May 30;8(22):36225-36245. doi: 10.18632/oncotarget.16717.

33.

Label-free identification of activated T lymphocytes through tridimensional microsensors on chip.

Rollo E, Tenaglia E, Genolet R, Bianchi E, Harari A, Coukos G, Guiducci C.

Biosens Bioelectron. 2017 Aug 15;94:193-199. doi: 10.1016/j.bios.2017.02.047. Epub 2017 Mar 3.

PMID:
28284079
34.

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.

Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL Jr.

Oncoimmunology. 2016 Oct 18;5(12):e1240857. doi: 10.1080/2162402X.2016.1240857. eCollection 2016.

35.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Review. Erratum in: Nat Rev Cancer. 2017 Sep 15;:.

36.

Combine and Conquer: Double CTLA-4 and PD-1 Blockade Combined with Whole Tumor Antigen Vaccine Cooperate to Eradicate Tumors.

Homicsko K, Duraiswamy J, Doucey MA, Coukos G.

Cancer Res. 2016 Dec 1;76(23):6765-6767. No abstract available.

37.

Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.

Monk BJ, Facciabene A, Brady WE, Aghajanian CA, Fracasso PM, Walker JL, Lankes HA, Manjarrez KL, Danet-Desnoyers GH, Bell-McGuinn KM, McCourt CK, Malykhin A, Hershberg RM, Coukos G.

Clin Cancer Res. 2017 Apr 15;23(8):1955-1966. doi: 10.1158/1078-0432.CCR-16-1453. Epub 2016 Oct 4.

38.

Radiotherapy combination opportunities leveraging immunity for the next oncology practice.

Herrera FG, Bourhis J, Coukos G.

CA Cancer J Clin. 2017 Jan;67(1):65-85. doi: 10.3322/caac.21358. Epub 2016 Aug 29. Review.

39.

Neoantigen-based cancer immunotherapy.

Bobisse S, Foukas PG, Coukos G, Harari A.

Ann Transl Med. 2016 Jul;4(14):262. doi: 10.21037/atm.2016.06.17. Review.

40.

1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).

Röhrig UF, Majjigapu SR, Caldelari D, Dilek N, Reichenbach P, Ascencao K, Irving M, Coukos G, Vogel P, Zoete V, Michielin O.

Bioorg Med Chem Lett. 2016 Sep 1;26(17):4330-3. doi: 10.1016/j.bmcl.2016.07.031. Epub 2016 Jul 16.

PMID:
27469130
41.

Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.

Zsiros E, Dangaj D, June CH, Kandalaft LE, Coukos G.

Oncoimmunology. 2015 Oct 19;5(5):e1062210. doi: 10.1080/2162402X.2015.1062210. eCollection 2016 May.

42.

[Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].

Martins F, Orcurto A, Michielin O, Coukos G.

Rev Med Suisse. 2016 May 18;12(519):989-93. French.

PMID:
27424426
43.

Traitement des cancers: n'oublions pas les enjeux humains et sociaux des progrès actuels et à venir!

Dietrich PY, Coukos G, Aapro M.

Rev Med Suisse. 2016 May 18;12(519):963-4. French. No abstract available.

PMID:
27424421
44.

Mass spectrometry-based antigen discovery for cancer immunotherapy.

Bassani-Sternberg M, Coukos G.

Curr Opin Immunol. 2016 Aug;41:9-17. doi: 10.1016/j.coi.2016.04.005. Epub 2016 May 4. Review.

PMID:
27155075
45.

Opportunities in immunotherapy of ovarian cancer.

Coukos G, Tanyi J, Kandalaft LE.

Ann Oncol. 2016 Apr;27 Suppl 1:i11-i15. doi: 10.1093/annonc/mdw084. Review.

46.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G.

Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685. Review.

PMID:
27075624
47.

TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer.

Bron S, Henry L, Faes-Van't Hull E, Turrini R, Vanhecke D, Guex N, Ifticene-Treboux A, Marina Iancu E, Semilietof A, Rufer N, Lehr HA, Xenarios I, Coukos G, Delaloye JF, Doucey MA.

Oncoimmunology. 2015 Aug 20;5(2):e1073882. eCollection 2016 Feb.

48.

TCR-engineered T cells to treat tumors: Seeing but not touching?

Debets R, Donnadieu E, Chouaib S, Coukos G.

Semin Immunol. 2016 Feb;28(1):10-21. doi: 10.1016/j.smim.2016.03.002. Epub 2016 Mar 17. Review.

PMID:
26997556
49.

Targeting Programmed Cell Death 1 in Ovarian Cancer.

Homicsko K, Coukos G.

J Clin Oncol. 2015 Dec 1;33(34):3987-9. doi: 10.1200/JCO.2015.63.7785. Epub 2015 Oct 26. No abstract available.

PMID:
26503205
50.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

Supplemental Content

Loading ...
Support Center